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bjectives The purpose of this study was to compare outcomes for drug-eluting stents (DES) and
are-metal stents (BMS) for patients with ST-segment elevation myocardial infarction (STEMI).
ackground Despite some controversy related to late stent thromboses, DES are approved for use
n many patients undergoing stenting. However, there are several types of patients in whom im-
lanting a DES would be regarded as off-label use, and this study compares DES and BMS for one
f these groups.
ethods New York’s percutaneous coronary intervention registry was used to identify 772 patients
ndergoing percutaneous coronary intervention (PCI) for STEMI who received BMS and 1,154 STEMI
atients who received DES between October 1, 2003, and December 31, 2004. These patients were
racked through December 31, 2005. Mortality, target vessel PCI, and subsequent coronary artery
ypass graft (CABG) surgery within 2 years of undergoing the procedure were captured. Adverse
utcomes were adjusted using proportional hazards methods to account for baseline differences in
atients’ severity of illness.
esults The BMS patients had signiﬁcantly higher mortality (adjusted hazard ratio [HR] vs. DES 
.01, 95% conﬁdence interval [CI] 1.21 to 3.34, risk-adjusted mortality  8.6% vs. 5.0%, p  0.007)
nd signiﬁcantly higher subsequent CABG surgery (adjusted HR vs. DES  2.33, 95% CI 1.31 to 4.16,
isk-adjusted rate  6.4% vs. 3.0%, p  0.004) rates. There was no difference by type of DES (ad-
usted HR for paclitaxel-eluting stent versus sirolimus-eluting stent; mortality 0.72, 95% CI 0.30 to
.72), subsequent CABG surgery (adjusted HR  0.60, 95% CI 0.26 to 1.40), and target vessel PCI
adjusted HR  0.74, 95% CI 0.35 to 1.58).
onclusions In this observational study, DES were associated with lower mortality and subsequent
ABG surgery when used for STEMI patients. (J Am Coll Cardiol Intv 2008;1:129–35) © 2008 by the
merican College of Cardiology Foundation
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130espite the fact that stenting has largely replaced conventional
alloon angioplasty as the preferred mode of percutaneous
oronary intervention (PCI) in the last several years, there
xists considerable controversy as to the relative merits of
are-metal stents (BMS) and drug-eluting stents (DES) or for
hat types of patients each type of stent is superior (1–19).
See page 136
Current Food and Drug Administration approval has re-
tricted DESs to short de novo lesions in native coronary
rteries between 2.5 and 3.5 mm in length for sirolimus-eluting
tents (SES) (20) and between 2.5 and 3.75 mm for paclitaxel-
luting stents (PES) (21). Patients with long or complicated
esions, chronic total occlusions, vein graft disease, multivessel
coronary artery disease, or urgent
coronary syndromes (including
ST-segment elevation myocardial
infarction [STEMI]) are not in-
cluded.
Few studies have compared out-
comes of DES and BMS for off-
label uses despite the fact that
off-label use of DES constitutes a
high percentage of all stent cases.
Although some randomized con-
trolled trials (RCTs) have com-
pared BMS and DES for STEMI
patients, those studies were quite
small and somewhat inconclusive
(22–25). The purpose of this
study is to examine 1 particular,
important type of off-label use, for
STEMI patients, and to docu-
ment the use of DES for these
patients in a population-based
study. Also, adverse outcomes for
STEMI patients with BMS are
compared with adverse outcomes
ith DES after adjusting for baseline differences in patient risk
actors.
ethods
atabases. Data were obtained from New York State’s
ercutaneous Coronary Interventions Reporting System
PCIRS), a mandatory registry in New York that was
nitially developed in 1991 to collect detailed information
or each patient in the state who was undergoing PCI. The
CIRS contains information regarding demographics; pre-
rocedural risk factors; periprocedural complications; types
f devices used; extent of disease; vessels and lesions treated;
ates of admission, discharge, and procedure; discharge
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ABG  coronary artery
ypass graft
ES  drug-eluting stent(s)
R  hazard ratio
V  intravenous
CI  percutaneous
oronary intervention
CIRS  Percutaneous
oronary Interventions
eporting System
ES  paclitaxel-eluting
tent(s)
CT  randomized
ontrolled trial
ES  sirolimus-eluting
tent(s)
TEMI  ST-segment
levation myocardial
nfarctionisposition and destination; and hospital and operator hdentifiers. These data are matched to New York adminis-
rative data and are audited by the New York State Depart-
ent of Health’s utilization review agent to ensure com-
leteness and accuracy.
The PCIRS data were matched to New York’s vital
tatistics data so that these patients could be followed after
ischarge for evidence of subsequent death. Also, data from
ew York’s Cardiac Surgery Reporting System were used
long with PCIRS data to identify repeat target vessel PCIs
nd subsequent coronary artery bypass grafts (CABGs) after
ischarge through December 31, 2005.
atients and end points. All patients who had experienced a
TEMI within 12 h prior to undergoing stenting with
ither BMS or DES between October 1, 2003, and Decem-
er 31, 2004, were included in the study except patients who
ad been previously revascularized (264 patients), had left
ain disease (50 patients), had prior thrombolytic therapy
ithin 7 days (503 patients), were from out of state (58
atients), or had combinations of different stent types (166
atients). All other primary angioplasty patients undergoing
tenting between October 1, 2003, and December 31, 2004
772 BMS patients and 1,154 DES patients: total 1,926
atients) were followed through December 31, 2005. Of the
,154 DES patients, 706 received SES and 448 received
ES. End points were mortality, target vessel PCI, and
ubsequent CABG surgery. The PCI registry enabled us to
dentify the target vessels in the index admission because it
ontained information on attempted vessels. However, the
ABG registry did not contain attempted vessels, so sub-
equent target vessel revascularization was not available, and
ubsequent CABG surgery was used as the end point.
tatistical analysis. Differences between primary angioplasty
atients undergoing stenting with BMS and with DES in
he prevalence of various patient risk factors (demographics,
omorbidities, left ventricular function, hemodynamic state,
essels diseased, time since onset of symptoms) as well as
ifferences in in-hospital mortality and need for CABG
urgery in the same admission were tested using Fisher exact
est (for binary risk factors) and the chi-square test (for
ther risk factors).
To test for risk-adjusted differences in longer-term out-
omes (mortality, target vessel PCI, and subsequent CABG
urgery), stepwise Cox proportional hazard models with a
obust covariance matrix that accounts for correlation of
urvival times for individuals within a hospital or operator
luster (26) were developed for each adverse outcome
easure after having confirmed that the proportional haz-
rds assumption was justified (27). Candidate independent
ariables included the patient risk factors available in the
egistry. Also, individual hospitals were controlled for in the
odel in case outcomes were related to individual hospitals
s well the type of stent used. In an additional model,
ospital volumes were controlled for in lieu of individual
ospitals. Type of stent (BMS, DES) was used in each
m
a
t
c
2
m
a
p
a
H
w
r
t
o
i
b
T
f
P
c
t
t
a
c
C
R
M
a
T
i
s
i
i
t
0
e
f
3-vessel proximal LAD disease 5.7 4.4
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 2 , 2 0 0 8
A P R I L 2 0 0 8 : 1 2 9 – 3 5
Hannan et al.
DES and BMS for STEMI Patients
131odel as the study independent variable, and BMS/DES
djusted hazard ratios (HRs) were obtained by exponentia-
ion of the coefficient of that variable. Adjusted survival
urves were constructed for BMSs and DESs for each of the
outcomes using the Cox proportional hazards models and
ethods for calculating adjusted survival (28).
Each type of DES (SES, PES) was then compared
gainst BMS for each adverse outcome by creating similar
roportional hazards models with each of the DES types as
binary indicator variable and BMS as the reference. Again,
Rs and their confidence intervals were calculated. A SES
as compared directly with a PES for each outcome by
estricting the database to DES patients and using PES as
he reference and SES as an indicator variable.
To test for selection bias, a propensity model was devel-
ped (29,30). The risk factors in Table 1 were used as
ndependent variables in a logistic regression model with a
inary dependent variable representing the use of BMS.
he propensity score was subdivided into quintiles and HRs
or DES/BMS mortality, CABG surgery, and target vessel
CI were compared for each quintile. Hazard ratios were
ompared across quintiles for each outcome to determine if
here was any tendency for them to be affected by the
endency to use a BMS versus a DES. All tests were 2-sided
nd conducted at the 0.05 level, and all analyses were
onducted in SAS 9.1 (SAS Institute Inc., Cary, North
arolina).
esults
ean follow-up times were 619 days for BMS (SD  183)
nd 522 days for DES (SD  142). As demonstrated in
able 1, STEMI patients undergoing BMS and DES
mplantation had very similar characteristics. The only
ignificant differences were with regard to Hispanic ethnic-
ty (9.6% for BMS vs. 6.7% for DES, p  0.024), and
ntravenous (IV) GP IIb/IIIa platelet inhibitors given prior
o the operation (65.4% for BMS vs. 56.8% for DES, p 
.001). Although BMS patients had higher observed and
xpected mortality and same-stay CABG rates, these dif-
Table 1. Continued
Risk Factor
BMS Implanted
(n  772)
DES Implanted
(n  1,154)
p
Value
Infarct vessel 0.25
LAD 39.9 43.7
LCX 16.3 15.6
RCA 43.8 40.7
BMS bare-metal stent; DES drug-eluting stent; GP glycoprotein; IV intravenous; LAD
left anterior descending; LCX  left circumflex; pre-op  prior to the operation; RCA  right
coronary artery; STEMI ST-segment elevation myocardial infarction.Table 1. Baseline Characteristics of STEMI Patients Undergoing Stent
Implantation for the First Time in New York from October 2003 to
December 2004
Risk Factor
BMS Implanted
(n  772)
DES Implanted
(n  1,154)
p
Value
Age, yrs 0.88
50 23.7 24.7
50 to 59 28.8 29.7
60 to 69 20.0 20.2
70 to 79 19.0 17.4
80  8.6 8.0
Interquartile range (median) 50–71 (59) 50–70 (58)
Gender 0.92
Male 71.8 71.5
Female 28.2 28.5
Hispanic ethnicity 9.6 6.7 0.024
Race 0.52
White 87.1 88.1
Black 7.0 5.7
Other 6.0 6.2
IV GP IIb/IIIa platelet inhibitors pre-op 65.4 56.8 0.001
Ejection fraction (%) 0.10
 20 1.2 1.0
20 to 29 6.0 4.7
30 to 39 14.0 15.7
40 68.1 64.5
Missing 10.8 14.2
Interquartile range (median) 40–55 (45) 40–55 (45)
Myocardial infarction (hours prior) 0.20
 6 85.9 83.7
6 to 11 14.1 16.3
Carotid/cerebrovascular disease 3.8 3.7 1.00
Peripheral vascular disease 2.7 3.7 0.25
Hemodynamically unstable 3.8 4.0 0.90
Shock 1.4 1.2 0.69
Congestive heart failure 0.15
This admission 6.7 4.7
Before this admission 0.3 0.4
None 93.0 95.0
Malignant ventricular arrhythmia 1.4 1.3 0.84
Chronic obstructive pulmonary disease 5.2 3.6 0.08
Diabetes 14.5 14.2 0.89
Renal failure 0.88
Dialysis 0.4 0.3
Creatinine 2.5 mg/dl, no dialysis 0.7 0.6
No renal failure 99.0 99.1
Anatomic group 0.39
1-vessel with no LAD disease 36.0 33.0
1-vessel nonproximal LAD disease 9.6 12.3
1-vessel proximal LAD disease 18.0 17.0
2-vessel with no LAD disease 6.9 7.9
2-vessel nonproximal LAD disease 8.8 9.9
2-vessel proximal LAD disease 10.1 10.3
3-vessel nonproximal LAD disease 4.9 5.2erences were not statistically significant (Table 2).
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132With regard to long-term outcomes, Table 3 indicates
hat the DES patients experienced lower unadjusted mor-
ality rates (unadjusted BMS/DES HR  1.53, 95% con-
dence interval [CI] 1.02 to 2.29) and subsequent CABG
urgery rates (unadjusted HR 1.74, 95% CI 1.12 to 2.71).
After adjusting for the individual hospital in which the
CI occurred, IV GP IIb/IIIa platelet inhibitors given prior
o the operation, the number of vessels diseased, region of
isease (left anterior descending involvement or proximal left
nterior descending involvement), age, female gender, ejection
raction, peripheral vascular disease, cerebrovascular disease,
emodynamic instability, shock, diabetes and renal failure,
ES patients continued to exhibit lower adverse outcome rates
Table 3). For mortality, the adjusted HR was 2.01, 95% CI
.21 to 3.34. For subsequent CABG surgery and target vessel
CI, the respective adjusted HRs were 2.33, 95% CI 1.31 to
.16 and 1.15, 95% CI 0.74 to 1.78. Adjusting for hospital
olumes in lieu of individual hospitals yielded similar results.
As indicated in Figure 1, the risk-adjusted mortality rates
t 2 years were 8.6% for BMS and 5.0% for DES, and this
ifference was significant (p  0.007). Figure 2 demon-
trates that the risk-adjusted rates for subsequent CABG
urgery were 6.4% for BMS and 3.0% for DES, and this
ifference was also significant (p  0.004). The rates were
.6% and 6.7% for target vessel PCI (Fig. 3), and this
ifference was not significant.
When we subdivided the DES patients into 706 SES
atients and 448 PES patients and repeated the analyses, we
ound that both SES and PES patients had significantly
ower mortality than BMS patients (for SES, adjusted HR
0.55, 95% CI 0.31 to 0.98, and for PES, adjusted HR 
.40, 95% CI 0.18 to 0.85; data not in tables). Both SES
nd PES were associated with lower subsequent CABG
ates than BMS (for SES, adjusted HR  0.52, 95% CI
.27 to 0.98, and for PES, adjusted HR  0.33, 95% CI
.14 to 0.76). With respect to target vessel PCI, there were
o significant differences (for SES/BMS, adjusted HR 
.11, 95% CI 0.69 to 1.79, and for PES/BMS adjusted HR
0.51, 95% CI 0.25 to 1.03).
After confining the analyses to patients who received
ither all SES or all PES, we found that there was no
Table 2. Short-Term Outcomes for STEMI Patients Undergoing
Stent Placement in New York from October 2003 to December 2004
Outcome
BMS
(n  772)
DES
(n  1,154) p Value
Observed in-hospital mortality rate (%) 2.46 1.39 0.12
Risk-adjusted in-hospital mortality rate (%) 2.39 1.42 0.14
Observed same-stay CABG rate (%) 1.04 0.52 0.27
Risk-adjusted same-stay CABG rate (%) 1.02 0.53 0.35
CABG coronary artery bypass graft; other abbreviations as in Table 1.ignificant difference between the 2 types of DES forortality (for PES/SES, adjusted HR  0.72, 95% CI 0.30
o 1.72; data not in tables). Also, there was no significant
ifference for subsequent CABG surgery (adjusted HR 
.60, 95% CI 0.26 to 1.40) or for target vessel PCI (adjusted
R  0.74, 95% CI 0.35 to 1.58).
With regard to the potential for selection bias, it should
rst be noted that the prevalence of important risk factors
as very similar for patients receiving DESs and BMSs for
rimary angioplasty. The only significant differences were
ith regard to Hispanic ethnicity and IV GP IIb/IIIa
latelet inhibitors given prior to the operation. Nevertheless,
propensity analysis was undertaken to test for selec-
ion bias.
In the propensity analyses, the propensity model demon-
trated low ability to identify predictors of DES use (C 
.58), which was not surprising given that Table 1 shows
hat the prevalence of patient risk factors were very similar
or DES and BMS patients. Despite this fact, the HR
avored DES (was 1) for all but 1 of the 15 quintile
omparisons across the 3 adverse outcome measures (1 for
ach measure), and there was no trend toward better
utcomes for BMS for the quintiles in which BMS were
sed more frequently.
iscussion
espite the fact that DES have proven to have lower
estenosis and repeat revascularization rates than BMSs in
umerous studies (1–15), some recent studies (16–19) have
eported higher late stent thrombosis rates in DES patients,
nd this has caused considerable concern about their safety.
A Food and Drug Administration panel that was con-
ened to examine the relative safety of DES and BMS
oncluded that DES are associated with a small increase in
tent thrombosis rates compared to BMS, but that this
roblem does not outweigh the benefits of DES (31).
It was also noted by the Food and Drug Administration
hat patient outcomes for off-label use may be worse than
hose observed for on-label use (31). In fact, 2 recent studies
onfirmed that when DES are used off-label, they are
Table 3. HRs (BMS/DES) for STEMI
Patients Undergoing Stent Placement in New York
Outcome
Unadjusted HR for
Primary Angioplasty
Cases BMS/DES
(95% CI)
Adjusted* HR for
Primary Angioplasty
Cases BMS/DES
(95% CI)
Mortality 1.53 (1.02–2.29) 2.01 (1.21–3.34)
CABG revascularization 1.74 (1.12–2.71) 2.33 (1.31–4.16)
Target vessel revascularization 1.25 (0.84–1.88) 1.15 (0.74–1.78)
*Adjusted for individual hospital, IV GPIIb/IIIa platelet inhibitors given prior to the operation,
number of vessels diseased, region of disease (LAD involvement or proximal LAD involvement),
age, femalegender, ejection fraction, peripheral vascular disease, cerebrovascular disease, hemo-
dynamic instability, shock, diabetes, and renal failure. HRhazard ratio; other abbreviations as inTables 1 and 2.
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133ssociated with higher adverse event rates than when they
re used on-label (32,33). However, this is not surprising
ecause the risk factors that constitute off-label use have
een demonstrated to be related to higher long-term ad-
erse outcome rates. What is most important is how DES
atients with risk factors associated with off-label use fare as
ompared with BMS patients with the same risk factors.
A recent meta-analysis of 7 RCTs has examined this issue
or patients with acute myocardial infarction. Combining
rials with a total of 1,177 DES patients and 1,180 BMS
atients with a follow-up of 8 to 12 months, Pasceri et al.
34) found that the incidence of death or myocardial
nfarction was not significantly different (5.8% for DES and
.9% for BMS, risk ratio  0.84, 95% CI 0.62 to 1.15).
Figure 1. Risk-Adjusted Mortality
Risk-adjusted mortality following primary percutaneous coronary intervention
versus drug-eluting stent (DES).
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Figure 2. Adjusted Rates of Subsequent CABGAdjusted rates of subsequent coronary artery bypass graft (CABG) following primaryarget lesion revascularization rates were lower for DES
atients (4.8% vs. 12.0%, risk ratio  0.40, 95% CI 0.30 to
.54).
Our study found that prior to adjustment, DES were
ssociated with significantly better outcomes (for mortality,
MS/DES HR  1.53, 95% CI 1.02 to 2.29, and for
ubsequent CABG surgery, HR  1.74, 95% CI 1.12 to
.71). After adjusting for patient factors related to adverse
utcomes as well as for the hospital in which stenting was
erformed, DES continued to have significantly better
utcomes (for mortality, adjusted HR 2.01, 95% CI 1.21
o 3.34, and for subsequent CABG surgery, adjusted HR 
.33, 95% CI 1.31 to 4.16), although repeat PCI was not
ignificant.
or ST-segment elevation myocardial infarction (STEMI): bare-metal stent (BMS)
25.1
s
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Year
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134Thus, our target vessel revascularization findings were
uite similar to those of large RCTs or meta-analyses of
CTs, in which DES were usually found to have signifi-
antly lower target vessel revascularization rates. However,
ur study is the first one to find a significant mortality
dvantage for DES, and the difference does not appear to be
erely a function of statistical power because our sample
izes are similar to those in some of the other studies.
It is also notable that there were no significant differences
n adjusted outcomes between SES and PES. Also, both
ypes of DES demonstrated a mortality and subsequent
ABG advantage compared with BMS.
tudy limitations. There are several limitations to the study.
irst, it is an observational study in which patients were not
andomized to DES and BMS, and therefore is subject to
oncerns related to selection bias, whereby 1 treatment may
ppear to have superior outcomes because the treatment was
ssociated with patients who had lower prevalences of risk
actors for adverse outcomes. We investigated this concern
y comparing risk factor prevalences for DES and BMS
atients and only found 2 variables (Hispanic ethnicity and
V GP IIb/IIIa platelet inhibitors given prior to the oper-
tion) for which there was a significant difference in
revalences. This was confirmed when we developed a
ropensity model that had very low ability to predict which
atients underwent DES versus BMS based on the numer-
us risk factors available in the registry. These results lead us
o conclude that because the advantage of DES was not
imited to groups of patients with very low probabilities of
ndergoing BMS, there is no evidence of selection bias with
espect to variables contained in the registry.
However, it should be noted that propensity matching
annot control for bias related to an imbalance in unknown
r unmeasured risk factors between the 2 interventions.
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Figure 3. Adjusted Rates of Subsequent PCI in Target Vessel
Adjusted rates of subsequent PCI in target vessel following primary PCI for STEactors that could influence PCI outcomes in general that dere not contained in the registry include vessel size, lesion
ength, clot burden, contraindication to antiplatelet medi-
ations, compliance with dual antiplatelet therapy, hyper-
ipidemia, limited life expectancy, active bleeding/bleeding
isk, and the use of statins and angiotensin-converting
nzyme inhibitors. Also, ejection fraction was treated as a
ategorical variable.
Another limitation is that myocardial infarction and stent
hrombosis were not included as end points. This is poten-
ially important considering the concern about stent throm-
osis in off-label use of DES, especially in patients with
TEMI.
Furthermore, the cause of death was unknown, and to the
xtent that the cause may have related to stenting more
mong DES patients, this would bias the study against
MS. Also, because the study was not a RCT, there were
o central blinded clinical event committees nor core
aboratories.
Another caveat is that because we used the New York
tate vital statistics data to track mortality after discharge
nd New York State registries to track subsequent CABG
nd target vessel PCI, we restricted the study to New York
tate patients. However, if patients moved outside of the
tate after discharge and then died or underwent revascu-
arization out of state, these events would have been missed
y our study. Also, the study would miss New York State
atients who underwent a repeat revascularization out of
tate. There is no reason why there would be a bias in favor
f either type of stent with respect to missed patients, and an
arlier study (35) demonstrated that there was not a bias in
his regard.
In conclusion, the mortality advantage in favor of DES is
ontrary to the results of RCTs, and as such is hypothesis
enerating, in particular because the possible mechanism un-
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135ould be at least partially related to selection bias, and it is
ecommended that a large, adequately powered clinical trial be
onducted to confirm or disprove the finding.
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